Stapokibart Found to Be Superior to Placebo for Severe Chronic Rhinosinusitis With Polyps

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, Aug. 20, 2025 -- In adults with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, the anti-interleukin 4Rα monoclonal antibody stapokibart improves outcomes, according to a study published online Aug. 18 in the Journal of the American Medical Association.

Shen Shen, from Capital Medical University in China, and colleagues assessed the efficacy and safety of stapokibart as an add-on treatment to intranasal corticosteroids in adults with severe uncontrolled chronic rhinosinusitis with nasal polyps. All 180 patients initiated mometasone furoate nasal spray (100 μg in each nostril daily) and then were randomly assigned (1:1) to stapokibart (300 mg) or placebo every two weeks for 24 weeks.

The researchers found that in the overall population, the least-squares (LS) mean change in nasal polyp score from baseline to week 24 was −2.6 in the stapokibart group versus −0.3 in the placebo group (LS mean difference, −2.3), and in the population with eosinophilia, the change was −3.0 versus −0.4 points, respectively (LS mean difference, −2.5). For nasal congestion, the score from baseline to week 24 in the stapokibart versus placebo groups was −1.2 versus −0.5 points, respectively, in the overall population (LS mean difference, −0.7) and −1.3 versus −0.5 points, respectively, in the population with eosinophilia (LS mean difference, −0.8). Serious adverse events were rare (2.2 percent with stapokibart versus 1.1 percent with placebo). In the stapokibart group, there were higher rates of arthralgia (7.8 percent versus 0 percent with placebo) and hyperuricemia (5.6 versus 1.1 percent).

"Compared with placebo, stapokibart rapidly and significantly reduced nasal polyp size, improved the main symptoms of rhinosinusitis, reduced overall sinus inflammation, and enhanced quality of life in both populations," the authors write.

Several authors disclosed ties to KeyMed Biosciences, the manufacturer of stapokibart.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-21 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords